SEKISUI Diagnostics Invests £14.4 Million in cGMP Biopharma CDMO Capacity
Burlington, MA, USA – July 29, 2020 – Sekisui announces the decision to invest £14.4 Million in its biopharma CDMO business aimed at cGMP microbial capacity expansion at the [...]
Sekisui Diagnostics Discusses Pandemic Response With MA State Representative Ken Gordon
Interviews with local companies in Massachusetts and how they have responded to the pandemic. Watch now!
Sekisui Diagnostics Announces FDA Clearance and CLIA Waiver of the OSOM® Ultra Plus Flu A&B Test
High performance, point-of-care rapid test for the detection of Influenza A&B The test utilizes traditional lateral flow technology with performance near or exceeding sensitivity of other reader-based tests without [...]
Sekisui Diagnostics Helping In Fight Against COVID-19
New to the Burlington, MA business community, Sekisui Diagnostics comes equipped to contribute to the ongoing effort against COVID-19. Watch now!
2020 IFCC Distinguished Award for Laboratory Medicine and Patient Care
Doctor David B. Sacks selected to receive the 2020 IFCC Distinguished Award for Laboratory Medicine and Patient Care Read Full Press Release
Sekisui Diagnostics Announces Distribution of SARS-CoV-2 Test
Sekisui Diagnostics announced today an agreement with Mesa Biotech to distribute their Accula™ SARS-Cov-2 Test which received Emergency Use Authorization (EUA) on March 23, 2020. The Accula™ SARS-CoV-2 Test [...]
SEKISUI CHEMICAL CO. LTD Named 2020 Global 100 Most Sustainable Corporations
SEKISUI CHEMICAL CO. LTD. was once again recognized as one of the ‘Most Sustainable Corporations in the World’ in Corporate Knights, 2020 Global 100 Index ranking 12th (out of [...]
Sekisui Diagnostics Opens $1.9 Million Bioprocess Innovation Centre
Burlington, MA, USA– 25th November 2019 – Sekisui Diagnostics’ Enzyme business unveiled its new Bioprocess Innovation Centre at its site near Maidstone, Kent, UK. The new R&D facility, costing [...]
Sekisui Invests $1.9m in New Bioprocess Innovation Centre in the UK
Click here for full story
Sekisui Diagnostics Announces FDA Clearance and CLIA Waiver of the AcucyTM Influenza A&B Test
Burlington, MA – October 8, 2019 –Sekisui Diagnostics announces the Acucy Influenza A&B Test has received 510(k) clearance as a Class II assay from the US Food and Drug [...]